The comprehensive midtrimester test: High-sensitivity Down syndrome test

American Journal of Obstetrics and Gynecology

Volumn 186, Issue 4, 2002, Pages 803-808

  Bahado Singh, Ray ^a   Shahabi, Shohreh ^a   Karaca, Mehmet ^a   Mahoney, Maurice J ^a   Cole, Laurence ^b   Oz, Utku A ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c MERSIN UNIVERSITY   (Turkey)

Author keywords

Down syndrome; Screening; Urine

Indexed keywords

ADULT; ALGORITHM; AMNIOCENTESIS; ARTICLE; BIOMETRY; DIAGNOSTIC TEST; DOWN SYNDROME; FEMALE; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SECOND TRIMESTER PREGNANCY; URINALYSIS;

EID: 0036257769     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2002.121651     Document Type: Article

References (25)

1. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation: Fetal Medicine Foundation First Trimester Screening Group
2. Integrated screening for Down's syndrome on the basis of tests performed during the first and second trimesters
3. Prenatal screening for Down's syndrome - A search for the family's values
4. Integrated test
5. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency
6. Urinary screening tests for fetal Down syndrome, II: Hyperglycosylated hCG
7. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening
8. Screening for Down syndrome pregnancy using beta-core fragment: Prospective study
9. Urinary screening tests for fetal Down syndrome, I: Fresh beta-core fragment
10. Comparison of 12 assays for detecting hCG and related molecules in urine samples from Down syndrome pregnancies
11. Combining beta-core fragment and total oestriol measurements to test for Down syndrome pregnancies
12. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of Down syndrome
13. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for down syndrome detection in high-risk pregnancies
14. New triple screen test for Down syndrome: Combined urine analytes and serum AFP
15. High-sensitivity alternative to "routine" genetic amniocentesis: Multiple urinary analytes, nuchal thickness, and age
16. Urine hyperglycosylated hCG plus ultrasound biometry for detection of down syndrome in the second trimester in a high-risk population
17. Nuchal thickness, urine beta-core fragment level, and maternal age for down syndrome screening
18. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome
19. Gestational age standardized nuchal thickness values for estimating mid-trimester Down's syndrome risk
20. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age
21. Maternal serum α-fetoprotein, age, and Down syndrome risk
22. Model based screening by risk with application to Down's syndrome
23. Triple-marker test as screening for Down syndrome: A meta-analysis
24. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: Population based cohort study
25. Outcome of chromosomally normal live births with increased fetal nuchal translucency at 10-14 weeks' gestation